In a move which can have a lasting impact in the biotech segment of the stocks market, Bristol-Myers Squibb Company (BMY) entered into a collaboration with Celgene Corporation (CELG) to asses the safety, tolerability and preliminary efficacy of a cocktail therapy including its high potential immuno-oncology drug Opdivo (nivolumab, a PD-1 immune checkpoint inhibitor) and…
There was nothing in the first-quarter results from narrowmoat Federated Investors FII that would alter our longterm view on the firm. With the company’s assets under management (AUM) so heavily skewed toward money market funds, Federated continues to be affected not only by historically low interest rates (which require the use of fee waivers to…
We will be maintaining our $55 fair value estimate and stable narrow moat trend for DTE Energy DTE after the company announced first-quarter earnings that were driven higher primarily by much colder weather for both the gas and the electric utilities. During the quarter, DTE earned $1.34 per share versus $0.91 per share for the…
Kite Pharma, Inc (KITE) announced the publication of positive results from an ongoing phase I-IIa study on KTE-C19 in patients suffering from aggressive non-Hodgkin’s lymphoma in the Aug 25, 2014 issue of the American Society of Clinical Oncology’s Journal of Clinical Oncology. In the phase I-II study, KTE-C19 achieved 92% overall objective response rate. According…
Shares of Amicus Therapeutics (FOLD) soared 20.4% after the company announced positive data from its second phase III study (Study 012) on the oral small molecule chaperone migalastat HCl in Fabry patients with amenable mutations. The phase III study is evaluating the use of oral migalastat to standard-of-care enzyme replacement therapies (ERTs) − Sanofi’s (SNY)…
No-moat, positive-moat-trend rated Autoliv ALV reported first-quarter earnings per share before special items of $1.32, $0.09 ahead of the Street consensus of $1.23. Even so, owing to lackluster European new-car demand and Autoliv’s European customers’ inventory corrections, the $1.32 first-quarter EPS were down $0.24 from $1.56 a year ago. However, management favorably tweaked its full-year…
